Blockchain Registration Transaction Record

Helus Pharma Surpasses 88% Enrollment in Phase 3 Depression Trial

Helus Pharma reports fiscal 2026 results, Phase 3 depression trial HLP003 surpasses 88% enrollment, topline data expected Q4 2026. HLP004 GAD study design due Q3 2026. Cash position $157.3M.

This news matters because Helus Pharma's progress with HLP003, a novel serotonergic agonist, could lead to a new treatment option for major depressive disorder, a condition affecting millions worldwide. The Phase 3 APPROACH trial's rapid enrollment suggests strong potential for addressing unmet needs in mental health. If successful, HLP003 could offer durable improvements in depression, especially for patients who do not respond to existing therapies. The company's robust cash position and ongoing pipeline development also indicate a commitment to advancing innovative therapies for anxiety and other mental health conditions, potentially transforming the treatment landscape.